Literature DB >> 3718809

Plasma amiodarone concentrations during intravenous infusion.

A H Watt, A Hutchings, M R Stephens, P A Routledge.   

Abstract

Amiodarone is a useful antiarrhythmic agent whose pharmacokinetics are incompletely characterised. In order to optimise efficacy of an antiarrhythmic drug, information regarding plasma concentrations achieved during use of the drug is necessary. We report plasma amiodarone and desethylamiodarone concentrations in eight patients following intravenous infusion at a rate of 175 mg h-1 for the first 2 h, followed by infusion at a rate of 50 mg h-1 for a further 46 h a regimen very similar to that recommended by the manufacturers. In at least three of eight patients plasma concentrations were below the suggested therapeutic range of 1.0-2.5 mg l-1 from 3 to 16 h after the infusion was started. Our data suggests that larger doses of intravenous amiodarone than those previously recommended may be necessary to obtain optimal benefit from the drug.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3718809      PMCID: PMC1401038          DOI: 10.1111/j.1365-2125.1986.tb02836.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  The method of separate exponentials: a simple aid to devising intravenous drug-loading regimens.

Authors:  D G Shand; R E Desjardins; T D Bjornsson; S C Hammill; E L Pritchett
Journal:  Clin Pharmacol Ther       Date:  1981-04       Impact factor: 6.875

2.  Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity.

Authors:  M Stäubli; J Bircher; R L Galeazzi; H Remund; H Studer
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of amiodarone.

Authors:  R Latini; G Tognoni; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

4.  Clinical efficacy of amiodarone in treatment of recurrent ventricular tachycardia and ventricular fibrillation.

Authors:  J J Heger; E N Prystowsky; D P Zipes
Journal:  Am Heart J       Date:  1983-10       Impact factor: 4.749

5.  Efficacy of amiodarone for refractory supraventricular tachyarrhythmias.

Authors:  T B Graboys; P J Podrid; B Lown
Journal:  Am Heart J       Date:  1983-10       Impact factor: 4.749

6.  Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias.

Authors:  C I Haffajee; J C Love; A T Canada; L J Lesko; G Asdourian; J S Alpert
Journal:  Circulation       Date:  1983-06       Impact factor: 29.690

7.  A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient.

Authors:  H J Wellens; P Brugada; H Abdollah; W R Dassen
Journal:  Circulation       Date:  1984-01       Impact factor: 29.690

8.  Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias.

Authors:  H L Greene; E L Graham; J A Werner; G K Sears; B W Gross; J P Gorham; P J Kudenchuk; G B Trobaugh
Journal:  J Am Coll Cardiol       Date:  1983-12       Impact factor: 24.094

9.  Pharmacokinetics of amiodarone in man.

Authors:  E Riva; M Gerna; R Latini; P Giani; A Volpi; A Maggioni
Journal:  J Cardiovasc Pharmacol       Date:  1982 Mar-Apr       Impact factor: 3.105

10.  Adverse reactions during treatment with amiodarone hydrochloride.

Authors:  B McGovern; H Garan; E Kelly; J N Ruskin
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.